Gilead Sciences, Inc.
NEWS
You don’t have to be a dairy farmer to like a cash cow.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
It’s no secret that the life sciences are increasingly international.
Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.
There are hundreds, even thousands of biotech and pharmaceutical companies.
Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.
CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
Gilead Sciences’ third-quarter financial results were dismal, to say the least.
JOBS
IN THE PRESS